NEPH vs. PYPD, PAVM, LYRA, MHUA, IINN, TTOO, MDAI, NMTC, GCTK, and FEMY
Should you be buying Nephros stock or one of its competitors? The main competitors of Nephros include PolyPid (PYPD), PAVmed (PAVM), Lyra Therapeutics (LYRA), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), T2 Biosystems (TTOO), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), GlucoTrack (GCTK), and Femasys (FEMY). These companies are all part of the "surgical & medical instruments" industry.
Nephros (NASDAQ:NEPH) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
PolyPid has a net margin of 0.00% compared to Nephros' net margin of -10.23%. Nephros' return on equity of -17.01% beat PolyPid's return on equity.
In the previous week, PolyPid had 5 more articles in the media than Nephros. MarketBeat recorded 12 mentions for PolyPid and 7 mentions for Nephros. PolyPid's average media sentiment score of 0.70 beat Nephros' score of 0.29 indicating that PolyPid is being referred to more favorably in the news media.
Nephros has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
PolyPid has a consensus target price of $14.00, suggesting a potential upside of 195.36%. Given PolyPid's higher probable upside, analysts plainly believe PolyPid is more favorable than Nephros.
Nephros has higher revenue and earnings than PolyPid. Nephros is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
41.1% of Nephros shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PolyPid received 12 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 74.19% of users gave PolyPid an outperform vote while only 39.29% of users gave Nephros an outperform vote.
Summary
PolyPid beats Nephros on 10 of the 16 factors compared between the two stocks.
Get Nephros News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
